Matthias Berninger’s Post

Berlin Center for Gene and Cell Therapies Kicked-off in Berlin Bayer and Charité - Universitätsmedizin Berlin recently unveiled plans to establish the Berlin Center for Gene and Cell Therapies, a translational center for gene and cell therapies. The project is supported by Germany’s Federal Government and the State of Berlin, aiming to bring these groundbreaking technologies to patients more quickly while creating a leading #biotech ecosystem for innovative #therapies in Berlin. Cell and gene therapies (#CGTs) have enormous potential. By targeting diseases at the genetic and cellular level, CGTs could offer options to people for whom conventional therapies have failed or where no effective treatment is currently available. Charité and Bayer will establish the center on the Bayer campus at Berlin Nordhafen. The center will support #startups bringing their innovative approaches in the area of cell therapies and gene therapies into clinical development. The center will include a fully equipped laboratory space and a production area certified according to the standards of good manufacturing practice (#GMP). Participating early-stage companies will receive advice on regulatory requirements, clinical trials, patent rights, and business development. Bayer and Charité will establish a joint public-private, non-profit company with limited liability. #Charité will own 67 percent of this company, with #Bayer owning the remaining 33 percent. Read more on #CMI online: https://lnkd.in/eS6pG8uy

xcellbio just announced a collaboration with ElevateBio to explore novel approaches towards improving therapeutic potency of cell and gene therapies. As part of this collaboration, ElevateBio becomes the first member of Xcellbio’s beta program for its new AVATAR Foundry™ device. As part of this collaboration, ElevateBio BaseCamp scientists will have access to Xcellbio’s AVATAR™ incubator system for cell therapy research and development as well as two new platforms: the AVATAR Ai™ system for measuring the potency of cell therapies and the AVATAR Foundry system for cGMP cell therapy manufacturing. The AVATAR and AVATAR Foundry systems are used to metabolically reprogram therapeutic cells to improve their potency and persistence in the tumor microenvironment (TME), while the AVATAR Ai provides real-time analysis of tumor cytotoxicity under TME conditions. These collaborative efforts should streamline manufacturing protocols for cell and gene therapies. https://lnkd.in/epz98hXB #cellandgenetherapy

🧬 Weekly Biotech Roundup: Key R&D Developments! This week brought significant advancements in biotech, particularly for early-stage companies making strides in innovative therapies. 🚀 CAR-T Cell Therapy Trials Update The FDA has lifted clinical holds on three CAR-T cell therapy trials. This decision allows early-stage biotechs to resume critical research. These trials are pivotal for companies aiming to expand their CAR-T options for various cancers. Notably, collaborations in this space could enhance treatment accessibility and efficacy. 👁️ Wet AMD Gene Therapy Approved An investigational new drug application for a gene therapy targeting wet age-related macular degeneration has received FDA clearance. This therapy, developed by a smaller biotech, highlights the potential of gene editing in treating eye diseases. As early-stage companies continue to innovate, partnerships with larger organizations could accelerate development timelines and bring novel treatments to patients faster. 🧬 CRISPR RNA Editing Breakthrough The FDA has approved a CRISPR-based RNA editing therapy developed with AI technology. This marks a significant milestone, as it showcases the power of integrating artificial intelligence in biotech research. Small firms focused on CRISPR technology are well-positioned to collaborate with tech companies, potentially reshaping therapeutic approaches for genetic disorders. 🔍 Insights and Opportunities The common thread among these developments is the collaboration between smaller biotechs and larger entities. This synergy is vital for driving innovation and improving patient outcomes. As a biotech staffing specialist, I am excited to support these early-stage companies and the talent that fuels their growth. Stay tuned for more updates as these companies continue to advance their groundbreaking work!

💎💎💎Whatsapp!! 💎💎💎Xcell Biosciences Expands AmplifyBio Gene Therapy Manufacturing Collaboration Xcell Biosciences expanded its collaboration with AmplifyBio, a CDMO, by installing a new AVATAR™ Foundry system as part of Xcellbio’s beta access program. The new instrument will enable AmplifyBio’s team to advance from small-scale workflows on the previously installed AVATAR™ Odyssey platform to achieve automated cell therapy manufacturing workflows suitable for clinical use, according to an Xcellbio spokesperson. Xcellbio and AmplifyBio have an ongoing collaboration aimed at streamlining and improving the manufacturing process for engineered #T_cell #receptor (TCR) #therapies #targeting #solid #tumors, which have proven difficult to treat with cell #therapies due to the #immunosuppressive #tumor #microenvironment. Through this collaboration, scientists are working to identify key elements for successful manufacture of TCR therapies, such as the relationship between various T cell conditioning #matrices and product characteristics such as #phenotype, #metabolic #profile, and #potency. Experiments already have progressed from in vitro to in vivo, and an IND filing is expected next year to target human #papillomavirus-positive tumors using a conditioned, engineered #TCR #therapy, continued the Xcellbio official. Xcellbio developed the AVATAR #platform for cell and gene therapy R&D with the AVATAR Odyssey system designed for small-scale research and process development needs. Its latest platform, the AVATAR Foundry system, is a cGMP manufacturing platform that delivers novel capabilities for improving the potency of cell and gene therapies, said J. Kelly Ganjei, president, and CEO of AmplifyBio. “Building on our experience with the AVATAR Odyssey system that is providing us with the tools to #optimize various T cell conditioning #protocols, we are excited to get access to the AVATAR Foundry system so we can progress our client’s research efforts toward automated, clinical-scale manufacturing of cell products,” continued Ganjei. ➡ 💎 You can find more pieces of work by clicking here. https://lnkd.in/eSG67K5G #T_cell #receptor

Exciting News from Berlin! Bayer AG and Charité – Universitätsmedizin Berlin have unveiled plans for the Berlin Center for Gene and Cell Therapies, set to become a leading biotech hub aimed at expediting groundbreaking cell and gene therapies to patients. Supported by Germany’s Federal Government and the State of Berlin, this state-of-the-art facility will feature GMP-certified production and an incubator for start-ups, with construction beginning in 2025. This initiative represents a unique collaboration between science, industry, and government, aiming to bridge the gap between research and patient care while positioning Berlin as an international biotech leader. By fostering innovation and supporting start-ups, the Berlin Center for Gene and Cell Therapies is set to pioneer the future of medicine and strengthen Germany's position in the global biotech ecosystem. #Biotech #GeneTherapy #CellTherapy #Healthcare

🌍 What We Can Learn from the Current Landscape of Approved Gene Therapies (Q3 2024) I want to introduce this insightful report, published by the American Society of Gene & Cell Therapy(ASGCT) and Citeline. This report analyzes several key insights and provides strategic implications.  Gene therapy continues to transform healthcare, with fascinating trends emerging globally. 🔬 Regional Leaders: - The U.S. dominates the field, driven by robust biotech infrastructure and regulatory support. - China is rapidly gaining ground, particularly in oncology, showcasing its growing R&D capabilities. * Please keep an eye on South Korea. Among the various candidates being developed by the country's innovative biotechs, which therapy will be approved as the country's first drug? 🩺 Key Focus Areas: - Oncology leads the way, addressing unmet needs in cancers like lymphoma and melanoma. - Rare diseases, such as hemophilia and spinal muscular atrophy, represent a significant share, highlighting opportunities in orphan drug development. 🌐 Strategic Opportunities: - Collaboration with the U.S. and China can unlock potential in oncology and rare diseases. - Europe remains a niche player, excelling in rare genetic disease therapies, but could expand further with its ATMP framework. - Emerging markets (e.g., Russia, Philippines) present untapped opportunities for technology transfer and regional trials. 🚀 Future Trends: - Advanced platforms like CAR-T and gene-editing technologies are shaping the next wave of innovation. - Companies focusing on scalable manufacturing and next-gen delivery systems will lead in accessibility and cost-effectiveness. Gene therapy's global growth emphasizes the need for cross-border collaboration and regulatory alignment. Let’s work together to unlock the full potential of this groundbreaking field! Ref) https://lnkd.in/gdphQ72t. #GeneTherapy #Innovation #Oncology #RareDiseases #Collaboration #GlobalHealth #Biotech #CRO #ClinicalResearch #CNRResearch

🧬 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬: 𝐓𝐡𝐞 𝐅𝐫𝐨𝐧𝐭𝐢𝐞𝐫 𝐨𝐟 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 The Gene Therapies for Cancer Treatment Market is rapidly evolving, driven by groundbreaking advancements in biotechnology and a growing focus on personalized medicine. Gene therapy involves modifying or manipulating genetic material within a patient’s cells to treat or prevent disease. In oncology, it offers innovative approaches to combat cancer by targeting the disease at a molecular level, enhancing efficacy, and reducing side effects compared to traditional therapies such as chemotherapy or radiation. With the increasing global cancer burden, there is an urgent need for novel and effective treatments. Gene therapies have emerged as a promising solution, addressing previously untreatable or resistant cancers. Techniques such as gene editing, viral vector-based gene delivery, and CAR-T cell therapies are at the forefront of innovation, enabling precise targeting of cancerous cells while preserving healthy tissues. 𝗖𝗹𝗶𝗰𝗸 𝗵𝗲𝗿𝗲 𝘁𝗼 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝘁𝗵𝗲 𝗳𝗿𝗲𝗲 𝗦𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝗽𝗼𝗿𝘁: https://lnkd.in/g9_zSq6T #Company Takara Bio USA, Inc. Tocagen VBL Therapeutics (Nasdaq:VBLT) Genprex, Inc. SynerGene Therapeutics ZIOPHARM Oncology, Inc. Anchiano Therapeutics Celgene Celsion Corporation bluebird bio #Type Somatic Cell Gene Therapy (SCGT) Germline Gene Therapy (GGT) #Applications Cancer Research Centers Diagnostic Laboratories Cancer Hospitals Others 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐁𝐮𝐲 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/g7pVKxU6 ✅ 𝐅𝐨𝐥𝐥𝐨𝐰-Stringent Datalytics - Healthcare #GeneTherapy #CancerTreatment #OncologyInnovation #PersonalizedMedicine #PrecisionOncology #Biotechnology #HealthTech #FutureOfHealthcare

Sharing an article on the 12 hottest biotechs in #Boston. Indeed all are innovative and well-funded, yet there are three that I find intriguing. Life Biosciences, MOMA Therapeutics, and Orna Therapeutics are leading the way in biotech innovation. Life Biosciences is redefining aging with programs for optic neuropathies and neurodegenerative disease. MOMA Therapeutics is discovering the next generation of precision medicines by targeting molecular machines that underlie human disease. Orna Therapeutics has developed circular RNA (oRNA) with applications across multiple disease areas, including cancer, regenerative medicine, protein replacement, infectious diseases, and autoimmunity. Their lead program is an in situ CAR therapy that combines oRNA™ molecules and proprietary lipid nanoparticles (LNPs) to deliver chimeric antigen receptors (CARs) directly to patient’s immune cells within the body (isCAR™ therapy). If you need help with your biotech commercialization, contact Russ at [email protected] or call 415-307-0774. #biotech #emergingbiotech #CEO #therapeutics #commercialization #funding #aging Read more about these innovative biotechs and others in Boston in this article: https://lnkd.in/gvj5S4W2

Sharing an article on the 12 hottest biotechs in #Boston. Indeed all are innovative and well-funded, yet there are three that I find intriguing. Life Biosciences, MOMA Therapeutics, and Orna Therapeutics are leading the way in biotech innovation. Life Biosciences is redefining aging with programs for optic neuropathies and neurodegenerative disease. MOMA Therapeutics is discovering the next generation of precision medicines by targeting molecular machines that underlie human disease. Orna Therapeutics has developed circular RNA (oRNA) with applications across multiple disease areas, including cancer, regenerative medicine, protein replacement, infectious diseases, and autoimmunity. Their lead program is an in situ CAR therapy that combines oRNA™ molecules and proprietary lipid nanoparticles (LNPs) to deliver chimeric antigen receptors (CARs) directly to patient’s immune cells within the body (isCAR™ therapy). If you need help with your biotech commercialization, contact Russ at [email protected] or call 415-307-0774. #biotech #emergingbiotech #CEO #therapeutics #commercialization #funding #aging Read more about these innovative biotechs and others in Boston in this article: https://lnkd.in/eza6aPA4

🚀 **This Week in Biotech: Breakthroughs and Collaborations** Exciting developments are shaping the biotech landscape this week, particularly for early-stage companies. 🎗️ **Orphan Drug Designation Granted** Immune-Onc Therapeutics’ IMM-1-104 received orphan drug designation for pancreatic cancer from the FDA. This designation could accelerate the drug’s development for this challenging disease, highlighting the potential of smaller biotechs in tackling significant health issues. 🧬 **CRISPR Advancements** Caribou Biosciences has made strides in ex vivo gene editing with their hybrid CRISPR guides. This innovative approach enhances precision in gene editing, positioning Caribou at the forefront of genetic therapies. Their technology could pave the way for more effective treatments, showcasing the importance of research in early-stage biotechs. 🧪 **Cell and Gene Therapy Updates** The latest updates from the cell and gene therapy sector reveal several collaborations. Notably, TCR2 Therapeutics announced a partnership to develop next-generation T cell therapies. Such collaborations between larger companies and nimble startups are crucial for advancing therapeutic options and optimizing development pathways. 📊 **Why It Matters** These stories highlight the dynamic nature of the biotech field, especially the role of smaller companies in driving meaningful change. As a biotech staffing specialist, I’m excited to support these innovators and contribute to their growth. The advances in gene editing and the recognition of orphan drugs solidify the importance of focusing on early-stage biotech. Let's continue to champion these breakthroughs as we move toward a healthier future!